Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT01844986
What this trial is testing

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Who this might be right for
Newly DiagnosedAdvanced Ovarian CancerFIGO Stage III-IV+4 more
AstraZeneca 450
Not applicableUnknownNCT06242392
What this trial is testing

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Fujian Cancer Hospital 250
Not applicableApproved For MarketingNCT03079687
What this trial is testing

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Who this might be right for
Ovarian Cancer
AstraZeneca
Testing effectiveness (Phase 2)WithdrawnNCT05295589
What this trial is testing

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Who this might be right for
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal Carcinoma+9 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT02734004
What this trial is testing

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

Who this might be right for
OvarianBreastSCLC+1 more
AstraZeneca 264
Testing effectiveness (Phase 2)Active Not RecruitingNCT03953898
What this trial is testing

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+4 more
National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)UnknownNCT01788332
What this trial is testing

Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)

Who this might be right for
Non-small Cell Lung Cancer
Lisette Nixon 70
Testing effectiveness (Phase 2)Ended earlyNCT04030559
What this trial is testing

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Who this might be right for
ATM Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+14 more
University of California, Davis 11
Testing effectiveness (Phase 2)Study completedNCT03462342
What this trial is testing

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer

Who this might be right for
High Grade Serous Carcinoma
University of Pennsylvania 123
Testing effectiveness (Phase 2)Active Not RecruitingNCT02286687
What this trial is testing

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Who this might be right for
Advanced Malignant NeoplasmATM Gene MutationBRCA1 Gene Mutation+5 more
M.D. Anderson Cancer Center 150
Early research (Phase 1)Study completedNCT02049593
What this trial is testing

PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Metastatic CancerUnspecified Adult Solid Tumor
Jonsson Comprehensive Cancer Center 44
Not applicableActive Not RecruitingNCT07303218
What this trial is testing

The HER Project: HRD in EGFR-mutated NSCLC

Who this might be right for
EGFRNon Small Cell Lung CancerHomologous Recombination Deficiency+1 more
IRCCS San Raffaele 100
Early research (Phase 1)Study completedNCT03075462
What this trial is testing

Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Who this might be right for
Ovarian CancerTriple Negative Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 98
Testing effectiveness (Phase 2)Ended earlyNCT04276376
What this trial is testing

Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

Who this might be right for
Solid Tumor
Gustave Roussy, Cancer Campus, Grand Paris 130
Not applicableUnknownNCT04782089
What this trial is testing

Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer
Qilu Hospital of Shandong University 20
Early research (Phase 1)Active Not RecruitingNCT05787587
What this trial is testing

PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+6 more
IDEAYA Biosciences 216
Not applicableStudy completedNCT06660147
What this trial is testing

Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

Who this might be right for
Ovarian Cancer
ARCAGY/ GINECO GROUP 243
Early research (Phase 1)Study completedNCT01063816
What this trial is testing

ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
AbbVie (prior sponsor, Abbott) 79
Early research (Phase 1)WithdrawnNCT02686008
What this trial is testing

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck
Yale University
Testing effectiveness (Phase 2)Looking for participantsNCT06819215
What this trial is testing

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

Who this might be right for
CancerNeoplasmsNeoplasms, Breast+8 more
Zhejiang Yangli Pharmaceutical Technology Co., Ltd. 188
Next Page